About Us
BioEclipse Therapeutics™ is preparing to enter open Phase I/IIa clinical trials with an intravenously-delivered, targeted biotherapy against solid tumors. Our first-in-class immunotherapy, CRX-100, delivers potentially curative treatments to patients over a broad range of tumor types, including hard-to-treat cancers that many consider untreatable.
16055
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16055,page-parent,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive
 

About Us

lab-scientist

Company Overview & Vision

 

BioEclipse Therapeutics™ is a clinical-stage oncology company that uses its proprietary technology to develop the next generation of immuno-oncology therapeutics.

 

Foundationally, we have harnessed a refined understanding of the human immune system, gaining insights into the reasons the body’s defense system so often turns a blind eye to the presence of cancerous cells and tumors.  In response, BioEclipse Therapeutics™ pairs activated immune cells with an adapted oncolytic virus that selectively infects and kills malignant cells. The result of this combination is a multi-mechanistic, targeted treatment that we believe will not only eradicate cancer cells, but also protect the patient from relapse and recurrence, through a durable immune response that prevents the development of new cancers, even in the face of new challenges from disease.

 

Meet BioEclipse Leadership

Corporate History

 

BioEclipse Therapeutics™ was founded as ConcentRx Inc and was renamed in 2017, concomitant with launching our clinical strategy, with new funding and the build out of an experienced executive team and an independent Board of Directors. Our Board of Directors is now made up of life science company investors, and biopharmaceutical executives with product development and commercial expertise.

 

BioEclipse Therapeutics™ is preparing to enter open Phase I/IIa clinical trials with an intravenously-delivered, targeted biotherapy against solid tumors. Our first-in-class immunotherapy, CRX-100, delivers potentially curative treatments to patients over a broad range of tumor types, including hard-to-treat cancers that many consider untreatable. The first product from our platform, CRX-100, is made up of two components, both of which have been extensively tested in humans with an excellent safety profile. We are entering an open Phase 1 clinical trial in ovarian cancer.

BioEclipse-Stanford
cancer-cells

CRX-100

 

Lead Therapeutic Candidate CRX-100

A New Class in Combination Immunotherapy Cancer Treatments

  • Activated innate immune cells protect and deliver an oncolytic virus to the target
  • Intravenous, not intra-tumor delivery
  • Safety and tolerability of each therapeutic component confirmed in humans
  • Millions of viral particles delivered directly to the tumor, where they replicate and kill millions of cancer cells to debulk large tumors
  • Multi-mechanistic; potential application in multiple indications
  • Durable immune response prevents recurrence, potentially curative
  • Compelling animal data presented and published to support pursuit of development in humans here

 

The Scientific Foundation:  Our Unique Approach

Current cancer therapies, including immunotherapies, have several major shortcomings. We address these by combining activated cytokine-induced killer cells (CIK) cells and an oncolytic virus, which if taken as individual therapies, are well tested in humans with excellent safety profiles, but limited efficacy.  Combined, the two agents work synergistically to find and kill cancer cells, creating a powerful, next-generation cancer immuno-therapy.  Importantly, this combination therapy specifically targets solid and liquid tumors, attacking them on multiple fronts by releasing the oncolytic virus from an expanded/enriched population of CIK cells that have the ability to specifically traffic to and bind to tumor cells.  The benefits of this approach include:

  • The compound acts as both a protector and carrier, activating the patient’s immune cells and enabling them to deliver a cancer-killing virus payload;
  • Eradicates malignant cells and creates a long-term (durable) immune response that prevents new cancer growth (relapse or recurrence);
  • High effector-to-target ratio (1million:1) allows for the debulking of large tumors; kills metastatic tumors,
  • Can be made from the patient’s own CIK cells or donor cells; and
  • Donor cells are not rejected by host, so repeat treatments are possible, if needed.

 

Conclusion:  CRX-100 is both precise and systemic – It only targets tumor cells, leaving healthy tissue untouched, but it has the ability to reach tumors all over the body.  This means the compound holds promise for metastatic disease treatment with limited toxicity.

Developing targeted Biotherapy to deliver CURATIVE treatment to patients with cancer.